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Introduction
The epithelial component of normal and non-invasive breast
tissues is normally surrounded by a layer of myoepithelial
(ME) cells, whose absence or disruption is an absolute pre-
requisite for tumor invasion and metastasis [1]. ME cells
are not easily identifiable in hematoxylin/eosin (H&E)-
stained breast tissue sections, as they are often indistin-
guishable from subjacent myofibroblastic cells in the
stroma. Immunohistochemical staining for smooth muscle
actin (SMA) has been routinely used to assist in the identifi-
cation of ME cells [2]. However, we and others have
repeatedly noted that about 4–6% of morphologically rec-
ognizable ME cells in H&E-stained sections fail to display
SMA immunoreactivity [3,4]. We attempted to assess
whether these SMA-negative cells also lack the expression
of eight additional markers that are supposed to present
exclusively or preferentially at ME cells.
Materials and methods
Case selection
Formalin-fixed, paraffin-embedded tissue blocks from
female patients with breast lesions were retrieved from
files of the Armed Forces Institute of Pathology. Consecu-
tive sections at 4–5µm thickness were cut and placed on
CK = cytokeratin; ER = estrogen receptor; H&E = hematoxylin/eosin; ME = myoepithelial; SMA = smooth muscle actin; SM-MHC = smooth muscle
myosin heavy chain; WT-1 = Wilms’ tumor-1.
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Abstract
Introduction: Immunostaining for smooth muscle actin (SMA)
is commonly used to elucidate mammary myoepithelial (ME)
cells, whose presence or absence is a reliable criterion for
differentiating in situ and invasive carcinomas. However, some
morphologically distinct ME cells fail to stain for SMA. This
study intended to assess whether these SMA-negative cells
also lack the expression of other ME cell markers.
Methods: Hematoxylin/eosin and SMA immunostained
sections from 175 breast cancer patients were examined.
Three cases were found to harbor ducts that showed
morphologically distinct ME cell layers, but showed no SMA
immunostaining in at least one-third of the layer or the entire
layer. Eight additional consecutive sections from each case
were stained for SMA, using a black chromogen, and each was
then re-stained for one of eight additional markers supposed to
exclusively or preferentially stain ME cells, using a red
chromogen. SMA-negative ME cells were re-examined for the
expression of other markers.
Results: SMA-negative ME cells in two cases also failed to
display immunoreactivity for other markers, including calponin,
CD10, smooth muscle myosin heavy chain, protease inhibitor 5
(maspin), Wilms’ tumor-1, and cytokeratins 5, 14, and 17
(CK5, CK14, and CK17). However, in one case SMA-negative
ME cells displayed immunoreactivities for maspin, CK5, CK14,
and CK17. The distribution of these ME cells is independent of
ductal size, length, and architecture.
Conclusions: A subset of morphologically identifiable ME cells
lack the expression of nine corresponding immunophenotypic
markers, suggesting that ME cells might also be subject to
different normal and pathological alterations.
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positively charged microscopic slides. A total of 175
cases with distinct ME cells, defined as a continuous layer
of spindle- or cuboid-shaped cells that overlie the base-
ment membrane and encircle epithelial cells, were
selected for this study. Among the 175 cases, all con-
tained non-invasive lesions, including ductal and lobular
carcinoma  in situ and sclerosing adenosis, and a few
cases had invasive components.
Markers and reagents
Nine antibodies reported to present exclusively or prefer-
entially at ME cells were selected for this study [5–25]
(Table 1); these included antibodies against SMA, smooth
muscle myosin heavy chain (SM-MHC), CD10, calponin,
protease inhibitor 5 (maspin), Wilms’ tumor-1 (WT-1), and
cytokeratins 5, 14, and 17 (CK5, CK4, and CK17). Other
reagents, including the secondary antibody, detection kits,
and chromogen kits, were purchased from Vector Labora-
tories, Inc (Burlingame, CA). Digestion enzymes recom-
mended for antigen retrieval were bought from Sigma (St
Louis, MO). A microwave oven and pressure cooker des-
ignated for antigen retrieval, along with retrieval solutions,
were purchased from Biocare Medical (Walnut Creek,
CA).
Immunohistochemical staining
A preliminary study was performed to optimize the
immunostaining condition for all antibodies selected. First,
each of the nine antibodies was tested strictly in accor-
dance with the manufacturer’s recommended protocol,
including the methods of antigen retrieval and the length
of the primary antibody incubation time. Then, each anti-
body was tested with our published protocol, which
involves an overnight incubation of deparaffinized sections
at 70°C in the retrieval solution and an incubation for
3–4 hours or overnight of the primary antibody at about
25°C [26]. Two adjacent sections stained by using our
protocol and the manufacturer’s recommended protocols
were compared for specificity and sensitivity. As our pro-
tocol consistently yielded stronger and more distinct stain-
ing for all the antibodies, the final staining for all the 175
cases with SMA and a double immunostaining with addi-
tional markers in selected cases (see below) were per-
formed with our published protocol [26].
Double immunohistochemical staining
All H&E-stained and immunostained sections were
reviewed independently by at least two investigators. All
ducts lined by at least 50 epithelial cells were examined,
and three cases were found to contain ducts that dis-
played morphologically distinct ME cell layers in H&E-
stained sections, but ME cells in at least one-third of the
layer or the entire layer were devoid of SMA staining. Eight
consecutive sections from each of the three selected
cases were used for a double immunostaining with our
published protocols [26,27]. In brief, all eight sections
were first immunostained for SMA with a black chro-
mogen. Each section was then stained for one of the eight
additional ME markers with a red chromogen. The same
ducts with SMA-negative ME cells were examined for the
expression of other markers. In addition, sections from all
three cases were immunostained for estrogen receptor
(ER) and CK8 to exclude the possibility that these SMA-
negative cells might be epithelial in nature.
Results and discussion
Results showed that all three cases spanned a morpho-
logic spectrum ranging from columnar cell hyperplasia to
ductal carcinoma in situ. Case 1 (columnar cell hyperpla-
sia) contained two ducts of interest lined by about
500 epithelial cells surrounded by morphologically distinct
ME cell layers on the H&E-stained section (Fig.1a). The
ME cells in about two-thirds of the ME layer showed dis-
tinct and strong SMA immunostaining, whereas the cells
Table 1
Antibodies used in this study
Antibody Company Clone Titer Staining pattern
Alpha-smooth muscle actin Novocastra αsm-1 1:50 Cytoplasmic
Maspin Novocastra EAW24 1:25 Cytoplasmic and nuclear
Calponin Novacastra CLAP 1:25 Cytoplasmic
Smooth muscle myosin heavy chain Dako SMMS-1 1:100 Cytoplasmic
Wilms’ tumor protein Cell Marque 6F-H2 1:10 Cytoplasmic
CD10 Novocastra 56C6 1:80 Cytoplasmic
Cytokeratin 5 Novocastra XM26 1:100 Cytoplasmic
Cytokeratin 14 Novocastra LL002 1:20 Cytoplasmic
Cytokeratin 17 Novocastra E3 1:20 CytoplasmicR153
in about one-third of the layer were devoid of SMA
immunostaining (Fig.1b). The SMA-positive and SMA-
negative cells were morphologically indistinguishable on
H&E-stained sections. In double immunostained sections,
these SMA-negative cells were also negative for SM-
MHC, WT-1, CD10, and calponin (Fig.1c–f). However,
these SMA-negative cells were positive for maspin, CK5,
CK14, and CK17 (Fig.1g–j).
Cases 2 and 3 contained ductal carcinoma in situ, of
intermediate grade and low grade, respectively. The ducts
were surrounded by morphologically distinct ME cell
layers in H&E-stained sections (Fig.2a). These ME cell
layers were attenuated, consisting of elongated spindle
cells with dark and compressed nuclei. The entire ME cell
layer was devoid of SMA immunostaining (Fig.2b). In
double immunostained sections, these SMA-negative cells
were also devoid of distinct immunostaining for any of the
additional eight markers (Fig.2c–f).
The SMA-negative cells in all three cases showed distinct
negativity to ER and CK8, in sharp contrast with the over-
lying epithelial cells that showed strong ER and CK8 posi-
tivities (data not shown). The distribution of these
SMA-negative ME cells seemed to be independent of the
ductal size, length, and architecture.
Our findings are consistent with those of a recent study
showing that a vast majority of the ME cells in both normal
and ductal carcinoma in situ displayed distinct immuno-
staining to p63, SM-MHC, and calponin, whereas a single
or a cluster of a few ME cells in some ducts failed to show
immunoreactivity to all these three markers [28]. However,
our study differs from this study [28] and previous studies
[3,4] in four aspects: first, the SMA-negative cells were
segmented, accounting for at least one-third or all of the
ME cells in involved ducts; second, we tested for more
ME cell markers; third, the SMA-negative cells assessed
were morphologically similar to their adjacent SMA-posi-
tive neighbors on H&E-stained sections; fourth, our focus
is directed toward the elucidation of the detailed immuno-
histochemical profile of these SMA-negative cells identi-
fied in 3 of 175 examined cases. The distribution of
different ME markers among normal, benign, and malig-
nant breast lesions in the remaining cases will be pre-
sented separately. In our study, p63 was replaced with
WT-1 for three main reasons: first, p63 is a nuclear
protein, which is not easily identifiable in attenuated or
compressed ME cells; second, previous studies have
shown that this protein is also expressed in ME-cell-
derived neoplasms and tumors with squamous cell differ-
entiation [29]; third, our preliminary study had showed that
WT-1 had the same subcellular localization but seemed to
be more specific for ME cells, compared with p63 [12].
The mechanism of the loss of myoepithelial markers in
some of the ME cells is unknown, but could result from the
dynamic and reciprocal interactions between epithelial
and ME cells. It has been documented that a variety of
proteolytic enzymes produced by malignant epithelial cells
could have substantial impacts on the physical integrity or
functions of the subjacent ME cells and the basement
membrane [30–32]. In contrast, ME cells could influence
the biological behavior of subjacent epithelial cells. Our
recent studies have revealed the co-localization of maspin
and WT-1 exclusively in mammary ME cells [12]. In a vast
majority of cases, the expression of these two proteins
decreases linearly with tumor progression, and the loss of
these proteins or focal disruptions in the ME cell layers
leads to a significantly higher cell proliferation in the subja-
cent epithelial cells [12,33]. In addition, these changes in
ME cells could result from effects of certain chemical
compounds.
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Figure 1
Immunostaining pattern of ME cells in columnar hyperplasia (case 1).
(a) H&E staining; (b) immunostaining for SMA; (c–f) double
immunostaining of SMA with SM-MHC, WT-1, CD10, and calponin,
respectively, and the segment of the ME layer is negative for all
antibodies; (g–j) double immunostaining of SMA with maspin, CK5,
CK14, and CK17, respectively, and the segment of the ME layer is
positive for all antibodies.It has been reported that the exposure to lambda-
carrageenan could specifically result in filament disassem-
bly and loss of ME cells [34]. In contrast, exposure to
oxytocin could substantially enhance ME cell differentia-
tion and proliferation in mouse breasts [35]. In addition,
these SMA-negative ME cells might be newly formed
through stem-cell-mediated proliferation and are in the
transition to a terminally differentiated status. Our previous
studies on animal models have shown that intercalated
duct cells in adult rat submandibular glands are the
common progenitor for both the acinar and granular duct
cells [27,36]. A recent study in human breast has revealed
that CK5-positive cells are capable of giving rise to both
glandular and ME cell lineages [21]. In both cases the
intermediate cells showed an unusual immunostaining
pattern for several proteins [21,36].
The total loss of all nine ME cell immunophenotypic
markers suggests that these ME cells have genetic and
biochemical properties differing from their SMA-positive
counterparts. The significance and consequence of these
changes in ME cells are unknown. However, given that the
disruption of the ME cell layer and basement membrane is
an absolute prerequisite for tumor invasion and metasta-
sis, these alterations in ME cells might affect the biological
behavior of the epithelial cells, making them prone to pro-
gression. Our assumption is in agreement with our previ-
ous findings, which have revealed that focal disruptions of
ME cell layers could lead to a significantly higher prolifera-
tion rate in subjacent epithelial cells [12,33]. Our assump-
tion is also supported by a recent study showing that
normal and tumor-derived ME cells differ substantially in
their ability to interact with luminal breast epithelial cells
for polarity and basement membrane deposition [37].
Further studies are currently in progress to elucidate the
biological behavior and genetic profile of epithelial cells
immediately subjacent to these SMA-negative ME cells.
Conclusions
A subset of morphologically identifiable ME cells lacks the
expression of nine corresponding immunophenotypic
markers, suggesting that, like the epithelial cells, ME cells
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Figure 2
Immunostaining pattern of ME cells in ductal carcinoma in situ (case 2). (a) H&E staining; (b) immunostaining for SMA; (c–f) double
immunostaining of SMA with maspin, CK5, CK14, and CK17, respectively, and the entire ME cell layer is negative for these antibodies in some
ducts and is also negative for SM-MHC, WT-1, CD10, and calponin (not shown).might also be subject to different normal and pathological
alterations, and that alterations in ME cells might signifi-
cantly affect the functions and biological behavior of the
adjacent epithelial cells.
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